{"entity":{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","aka":["Junshi","君实生物"],"tldr":"Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer).","summary":"Toripalimab (Tuoyi / Loqtorzi) has more than ten NMPA indications, US approval for nasopharyngeal carcinoma with Coherus (licence February 2021, $150 million upfront), and EU, UK and Australian approvals. Pipeline: the BTLA antibody tifcemalimab, a PD-1 x VEGF bispecific and ADCs. Junshi also co-developed the COVID-19 antibody etesevimab with Lilly.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.junshipharma.com/en/"},{"label":"Coherus licence (February 2021)","url":"https://investors.coherus.com/news-releases"}],"tags":["china"],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["toripalimab","js105","fluzoparib","js111"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["jupiter-02","jupiter-06","nct06679985"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.junshipharma.com/en/","ticker":"1877.HK / 688180.SS","founded":2012,"investors":[],"funding":[]},"route":"/companies/junshi/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"fluzoparib","kind":"drug","name":"Fluzoparib","route":"/drugs/fluzoparib/"},{"id":"js105","kind":"drug","name":"JS105","route":"/drugs/js105/"},{"id":"js111","kind":"drug","name":"JS111","route":"/drugs/js111/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"trial":[{"id":"nct06208410","kind":"trial","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","route":"/trials/nct06208410/"},{"id":"nct06885385","kind":"trial","name":"A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer","route":"/trials/nct06885385/"},{"id":"nct07207070","kind":"trial","name":"A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct07207070/"},{"id":"nct06679985","kind":"trial","name":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat","route":"/trials/nct06679985/"},{"id":"nct06505837","kind":"trial","name":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","route":"/trials/nct06505837/"},{"id":"nct07045311","kind":"trial","name":"JS207 Combination Therapy in Triple-negative Breast Cancer","route":"/trials/nct07045311/"},{"id":"nct07503756","kind":"trial","name":"JS212 Combination Therapies in Metastatic Colorectal Cancer","route":"/trials/nct07503756/"},{"id":"jupiter-02","kind":"trial","name":"JUPITER-02","route":"/trials/jupiter-02/"},{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","route":"/trials/jupiter-06/"},{"id":"neotorch","kind":"trial","name":"Neotorch","route":"/trials/neotorch/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}